ODYSSEY ESCAPE: Alirocumab cuts apheresis rates in familial hypercholesterolemia

(European Society of Cardiology) Patients who have heterozygous familial hypercholesterolemia, a condition that causes abnormally raised low-density lipoprotein cholesterol levels and premature cardiovascular disease, can significantly reduce or even eliminate their need for expensive and time-consuming apheresis treatments with the PCSK9 inhibitor alirocumab.